3832-48-2

Basic information

• Product Name: BROMODIFLUOROACETYL CHLORIDE
• Synonyms: BROMODIFLUOROACETYL CHLORIDE;Bromodifluoroacetyl chloride 97%;Bromodifluoroacetylchloride97%;acetyl chloride, bromodifluoro-;2-broMo-2,2-difluoroacetyl chloride;2-Bromo-2,2-difluoroethanoyl chloride
• CAS NO: 3832-48-2
• Molecular Formula: C₂BrClF₂O
• Molecular Weight: 193.37
• Mol File: 3832-48-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 50 °C
• Appearance: /
• Density: 2.053 g/cm³
• Vapor Pressure: 229mmHg at 25°C
• Refractive Index: 1.3853
• CAS DataBase Reference: BROMODIFLUOROACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: BROMODIFLUOROACETYL CHLORIDE(3832-48-2)
• EPA Substance Registry System: BROMODIFLUOROACETYL CHLORIDE(3832-48-2)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39
• RIDADR: 3265
• HazardClass: CORROSIVE
• Hazardous Substances Data: 3832-48-2(Hazardous Substances Data)

Usage

Description

Bromodifluoroacetyl Chloride is an organic compound with the chemical formula C2BrClF2O. It is a colorless to pale yellow liquid that is highly reactive due to the presence of the acyl chloride functional group. BROMODIFLUOROACETYL CHLORIDE is known for its ability to react with various nucleophiles, making it a versatile reagent in organic synthesis.

Uses

Used in the Chemical Synthesis Industry:
Bromodifluoroacetyl Chloride is used as a reagent for the preparation of Haloalkyl Acid Halides. These compounds are important intermediates in the synthesis of various organic molecules, including pharmaceuticals and agrochemicals.
Used in the Pharmaceutical Industry:
Bromodifluoroacetyl Chloride is used as a key intermediate in the synthesis of 3-Pyridinyl substituted Triazolopyrazines, Triazolopyridazines, and Triazolopyridines. These compounds are known as ion channel modulators, which have potential applications in the treatment of various neurological and cardiovascular disorders.

InChI:InChI=1/C2BrClF2O/c3-2(5,6)1(4)7

Upstream product

• 75-82-1 1,2-dibromo-1,1-difluoroethane 
• 421-36-3 2-Chloro-1,2-dibromo-1,1-difluoroethane 
• 558-57-6 1,2-dibromo-1,1-dichloro-2,2-difluoroethane 
• 66270-59-5 1,1-difluoro-1,2,2-tribromo-2-chloroethane 
• 354-08-5 bromodifluoroacetic acid 
• 15080-20-3 Methyl-(1,2-dibrom-1,2,2-trifluoraethyl)-aether 

Downstream Products

• 881391-37-3 4-[(2-bromo-2,2-difluoroacetyl)-(2-iodophenyl)amino]piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis and Biological Activity of Point-Fluorinated Pheromone Analogues of Eldana saccharina

Substitution of fluorine atoms on an organic molecule makes it possible to modify the molecular orbital and electron density of the surface without changing its molecular shape. Point-fluorinated analogues of the sex pheromone of the male African sugarcane borer were synthesized in optically active forms and their pheromone activities were investigated using an EAG test. The EAG activity of these point-fluorinated pheromone analogues indicates that the point of fluorination has a critical influence on the pheromone activity. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

Photo-triggered self-catalyzed fluoroalkylation/cyclization of unactivated alkenes: Synthesis of quinazolinones containing the CF2R group

A novel photo-triggered self-catalyzed fluoroalkylation/cyclization of quinazolinones containing unactivated alkenes with various fluoroalkyl bromides has been developed. This transformation exhibits excellent substrate generality with respect to both the coupling partners. Of note is that this is the first example describing the Csp3-Br bond homolysis of alkyl bromides via a substrate (quinazolinones) induced energy transfer process. Additionally, the mild conditions, tolerance to a wide range of functional groups and operational simplicity make this protocol practical for the synthesis of fluorine-containing ring-fused quinazolinones. This journal is

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.